Phase 3 Trial Shows Positive Results for Oral Acne Drug Denifanstat
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The once-daily FASN inhibitor met all primary and secondary endpoints for treating moderate to severe acne, with data to be presented at the EADV Congress.
The device, which uses ultrasound to stimulate collagen and elastin production, now includes treatment areas beyond the face and neck.